Evidence mapPaperPMID 39182092Full record

SynthesisAnnals of clinical microbiology and antimicrobials2024

Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.

Lingbo Guan, Masoumeh Beig, Lina Wang, Tahereh Navidifar, Samaneh Moradi, Faezeh Motallebi Tabaei, Zahra Teymouri, Mahya Abedi Moghadam, Mansour Sedighi

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Annals of clinical microbiology and antimicrobials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Genotypic features of antimicrobial resistance, virulence determinants, and clonal lineages of Enterococcus spp. reported in Brazil: a scoping review with marked regional asymmetry.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  3. In vitro activity of β-lactams against contemporary Enterococcus faecalis clinical isolates and performances of disc diffusion testing for prediction of β-lactam susceptibility.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Adaptation ofmSystems · 2026
    Article
  8. Article
  9. [In vitro and in vivo antibacterial effects of the mitochondrial antioxidant Visomitin againstZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Antimicrobial Resistance in Indicator MicroorganismsAnimals : an open access journal from MDPI · 2026
    Article
  16. Article
  17. One Health Insights intoInternational journal of molecular sciences · 2026
    Article
  18. Article
  19. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lingbo GuanDepartment of Intensive Care Unit, Linping Campus, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 311100, Zhejiang, China.
Masoumeh Beig *Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Lina WangDepartment of Intensive Care Unit, Linping Campus, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 311100, Zhejiang, China.
Tahereh Navidifar *Department of Basic Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.
Samaneh MoradiDepartment of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Faezeh Motallebi TabaeiDepartment of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. faezeh.mt66@gmail.com.
Zahra TeymouriLaboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mahya Abedi MoghadamLaboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mansour SedighiCellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran. mansour.sedighi60@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to the increasing emergence of antibiotic resistance in Enterococcus faecalis (E. faecalis), it indicated as potentially opportunistic pathogen causing various healthcare-associated and life-threatening diseases around the world.

objectiveThe aim of this meta-analysis was to evaluate the weighted pooled resistance rates in clinical E. faecalis isolates based on over time, areas, antimicrobial susceptibility testing (AST), and infection source.

methodsWe searched the studies in PubMed, Scopus, and Web of Science (November 30, 2022). All statistical analyses were carried out using the statistical package R.

resultsThe analysis encompassed a total of 74 studies conducted in 28 countries. According to the meta-regression, the chloramphenicol, fosfomycin, imipenem, linezolid, minocycline, norfloxacin, quinupristin-dalfopristin, and tetracycline resistance rate increased over time. Analysis revealed statistically significant differences in antibiotic resistance rates for ampicillin, chloramphenicol, erythromycin, gentamicin, penicillin, rifampicin, teicoplanin, tetracycline, and vancomycin across various countries.

conclusionsGlobally, the prevalence of drug resistant E. faecalis strains are on the increase over time. Daptomycin and tigecycline can be an effective agent for the treatment of clinical E. faecalis infections. Considering the low prevalence of antibiotic resistance in continents of Europe and Australia, it is suggested to take advantage of their preventive strategies in order to obtain efficient results in other places with high prevalence of resistance.

Indexed as

Anti-Bacterial AgentsEnterococcus faecalisGram-Positive Bacterial InfectionsMicrobial Sensitivity TestsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialGlobal HealthHumansAnti-Bacterial AgentsAntimicrobial resistanceClinical samplesEnterococcus faecalisSystematic review and meta-analysis

Identifiers

PMID39182092
PMCPMC11344933

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.